Lynparza, Keytruda Supplemental Indications Face US FDA Panel Review

 
• By Sue Sutter
  
PS1912_Cancer-treatment_296307902_1200.jpg
US FDA's ODAC will review four cancer drugs in two days. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers